U.S. Markets open in 7 hrs 57 mins

Biolase Inc (BIOL) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Biolase Inc (BIOL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Biolase Inc is a medical device company that develops, manufactures, and markets lasers in dentistry and medicine and also markets and distributes dental imaging equipment. Biolase Inc has a market cap of $55.770 million; its shares were traded at around $2.70 with and P/S ratio of 1.20. Biolase Inc had annual average EBITDA growth of 11.30% over the past five years.

For the last quarter Biolase Inc reported a revenue of $13.0 million, compared with the revenue of $12.63 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $46.2 million, a decrease of 1.6% from the previous year. For the last five years Biolase Inc had an average revenue decline of 2.8% a year.

The reported loss per diluted share was $1.05 for the year, compared with the loss per share of $2.112 in the previous year. The Biolase Inc had an operating margin of -39.43%, compared with the operating margin of -37.36% a year before. The 10-year historical median operating margin of Biolase Inc is -33.12%. The profitability rank of the company is 1 (out of 10).

At the end of the fiscal year, Biolase Inc has the cash and cash equivalents of $8.04 million, compared with $11.6 million in the previous year. The long term debt was $10.8 million. Biolase Inc has a financial strength rank of 5 (out of 10).

At the current stock price of $2.70, Biolase Inc is traded at close to its historical median P/S valuation band of $2.71. The P/S ratio of the stock is 1.20, while the historical median P/S ratio is 1.21. The stock gained 25.25% during the past 12 months.

For the complete 20-year historical financial data of BIOL, click here.

This article first appeared on GuruFocus.